Live attenuated arkansas serotype infectious bronchitis virus vaccine
AssigneeUniversity of Georgia Research Foundation, Inc.
InventorsBrian J. Jordan, Mark W. Jackwood
Life of this patent
Estimating the term…
Abstract
Attenuated isolates of the Arkansas serotype of infectious bronchitis virus (IBV), including the IBV isolate ArkGA p60 deposited at the ATCC under Patent Designation PTA-123783, and compositions thereof are presented. Methods for administering the isolates or compositions as vaccines to the prevent virulent IBV infection in birds of the order Galliformes also presented.
Claims20
An infectious bronchitis virus (IBV) isolate, wherein the IBV isolate comprises the IBV isolate ArkGA p60 deposited at the ATCC under Patent Designation PTA-123783.
An attenuated infectious bronchitis virus (IBV) isolate of the Arkansas serotype, the attenuated IBV isolate comprising an S1 glycoprotein subunit comprising an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO:
- 2, and wherein the S1 glycoprotein subunit comprises an asparagine residue at amino acid position 117 and/or a histidine residue at amino acid position 386.
The IBV isolate of claim 17, the attenuated IBV isolate comprising an S1 glycoprotein subunit comprising SEQ ID NO:
- 2.
An isolated S1 polypeptide comprising at least 90% sequence identity to SEQ ID NO:
- 2 and wherein the S1 polypeptide comprises an asparagine residue at amino acid position 117 and/or a histidine residue at amino acid position 386.
Dependencies are inferred from the claim text.